ArticleAntimicrobial agents and chemotherapy2018
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Physiologically Based Pharmacokinetic Modeling of Inhaled Polymyxin B: From Rabbit Optimization to Human Predictions.Pharmaceutical research · 2026Article
- Resistance, heteroresistance, and fitness costs drive colistin treatment failure duringProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Comparative study on the wound healing effects of local versus systemic application of Polymyxin B in mice infected with multidrug-resistantFrontiers in microbiology · 2026Article
- Resistance, heteroresistance and fitness costs drive colistin treatment failure duringbioRxiv : the preprint server for biology · 2025Article
- Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria.Antimicrobial agents and chemotherapy · 2025Article
- Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.Frontiers in microbiology · 2022Review
- PKPD Modeling of the Inoculum Effect ofFrontiers in pharmacology · 2022Article
- Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.International journal of pharmaceutics · 2021Article
- Rescuing the Last-Line Polymyxins: Achievements and Challenges.Pharmacological reviews · 2021Review
- In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.International journal of pharmaceutics · 2021Article
- Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.International journal of antimicrobial agents · 2020Review
- Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.Pharmaceutical research · 2020Article
- Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.Molecular pharmaceutics · 2020Article
- Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.International journal of pharmaceutics · 2020Article
- Effective pharmacotherapy for lung abscess in a patient with alcoholism.Respiratory medicine case reports · 2020Article
- Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae.Antimicrobial agents and chemotherapy · 2019Article
- Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.International journal of pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Yu-Wei LinAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia.
Qi Tony ZhouDepartment of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana, USA.
Mei-Ling HanDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia.
Ke ChenDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia.
Nikolas J OnufrakDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-2649-709X
Jiping WangDrug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria, Australia.
John D TurnidgeAustralian Commission on Safety and Quality in Health Care, Sydney, New South Wales, Australia.
Benjamin P HowdenMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia.
Alan ForrestDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, North Carolina, USA.
Hak-Kim ChanAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia kim.chan@sydney.edu.au jian.li@monash.edu.
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia kim.chan@sydney.edu.au jian.li@monash.edu.
Funding
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic CombinationsR01AI111965 · NIAID · MONASH UNIVERSITY · PI LI, JIAN · 2014 to 2018
$4.3MCombating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4MNIAID NIH HHS R01 AI111965NIAID NIH HHS R01 AI132681
Abstract
The pharmacokinetics/pharmacodynamics (PK/PD) of aerosolized colistin was investigated against
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsColistinDisease Models, AnimalDrug Resistance, Multiple, BacterialKlebsiella pneumoniaeLungMiceMicrobial Sensitivity TestsRespiratory Tract InfectionsAnti-Bacterial AgentsColistinAcinetobacter baumanniiGram-negative bacteriaKlebsiella pneumoniaepolymyxinpulmonary administrationrespiratory tract infections
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.